Kronos Bio, Inc. announced the appointment of Dr. Elizabeth Olek, DO, MPH, as senior vice president, Clinical Development. Dr. Olek joins Kronos Bio from Loxo Oncology at Lilly. Dr. Olek will be responsible for the planning, conduct and analysis of Kronos Bio's clinical trials, reporting to Jorge DiMartino, M.D., Ph.D., chief medical officer and executive vice president, Clinical Development.

Dr. Olek's role will also include oversight of the company's three current investigational drug candidates, entospletinib, lanraplenib and KB-0742, as well as future programs. Entospletinib, a spleen tyrosine kinase (SYK) inhibitor and the company's lead product candidate, is being evaluated in the pivotal Phase 3 AGILITY trial as a treatment for patients with NPM1-mutated acute myeloid leukemia. Kronos Bio is also currently conducting the dose-escalation stage of a Phase 1/2 trial with the cyclin dependent kinase 9 (CDK9) inhibitor KB-0742 in patients with solid tumors and plans to initiate two Phase 1b/2 clinical trials in the first half of this year with lanraplenib, the company's next-generation SYK inhibitor. Prior to Loxo Oncology at Lilly, Dr. Olek worked at Puma Biotechnology, leading a clinical program for neratinib in breast cancer.

Previously, Dr. Olek served as chief medical officer at Achillion Pharmaceuticals and in clinical leadership roles at Novartis.